Literature DB >> 20005135

MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase.

Iftach Shaked1, Ari Meerson, Yochai Wolf, Ran Avni, David Greenberg, Adi Gilboa-Geffen, Hermona Soreq.   

Abstract

MicroRNAs (miRNAs) contribute to both neuronal and immune cell fate, but their involvement in intertissue communication remained unexplored. The brain, via vagal secretion of acetylcholine (ACh), suppresses peripheral inflammation by intercepting cytokine production; therefore, we predicted that microRNAs targeting acetylcholinesterase (AChE) can attenuate inflammation. Here, we report that inflammatory stimuli induced leukocyte overexpression of the AChE-targeting miR-132. Injected locked nucleic acid (LNA)-modified anti-miR-132 oligonucleotide depleted miR-132 amounts while elevating AChE in mouse circulation and tissues. In transfected cells, a mutated 3'UTR miR-132 binding site increased AChE mRNA expression, whereas cells infected with a lentivirus expressing pre-miR-132 showed suppressed AChE. Transgenic mice overexpressing 3'UTR null AChE showed excessive inflammatory mediators and impaired cholinergic anti-inflammatory regulation, in spite of substantial miR-132 upregulation in brain and bone marrow. Our findings identify the AChE mRNA-targeting miR-132 as a functional regulator of the brain-to-body resolution of inflammation, opening avenues for study and therapeutic manipulations of the neuro-immune dialog. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005135     DOI: 10.1016/j.immuni.2009.09.019

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  193 in total

Review 1.  Epigenetic mechanisms in inflammation.

Authors:  D Bayarsaihan
Journal:  J Dent Res       Date:  2011-01       Impact factor: 6.116

Review 2.  Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?

Authors:  M Zimmermann
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

3.  Overexpression of circARF3 mitigates TNF-α-induced inflammatory damage by up-regulating miR-125b.

Authors:  Yingying Zhang; Binghui Hou; Chunxiao Li; Hong Li
Journal:  Cell Cycle       Date:  2020-04-24       Impact factor: 4.534

4.  Changes in microglial inflammation-related and brain-enriched MicroRNAs expressions in response to in vitro oxygen-glucose deprivation.

Authors:  Huimin Kong; Ahmed Omran; Muhammad Usman Ashhab; Na Gan; Jing Peng; Fang He; Liwen Wu; Xiaolu Deng; Fei Yin
Journal:  Neurochem Res       Date:  2013-12-12       Impact factor: 3.996

Review 5.  MicroRNAs in neuronal communication.

Authors:  Guilherme Shigueto Vilar Higa; Erica de Sousa; Lais Takata Walter; Erika Reime Kinjo; Rodrigo Ribeiro Resende; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2014-01-03       Impact factor: 5.590

Review 6.  Epigenetic mechanisms in stroke and epilepsy.

Authors:  Jee-Yeon Hwang; Kelly A Aromolaran; R Suzanne Zukin
Journal:  Neuropsychopharmacology       Date:  2012-08-15       Impact factor: 7.853

Review 7.  The interplay of microRNAs and post-ischemic glutamate excitotoxicity: an emergent research field in stroke medicine.

Authors:  Alireza Majdi; Javad Mahmoudi; Saeed Sadigh-Eteghad; Mehdi Farhoudi; Siamak Sandoghchian Shotorbani
Journal:  Neurol Sci       Date:  2016-06-27       Impact factor: 3.307

8.  MicroRNAs in Cerebral Ischemia.

Authors:  Kai-Ying Lim; Jia-Hui Chua; Jun-Rong Tan; Priyadharshni Swaminathan; Sugunavathi Sepramaniam; Arunmozhiarasi Armugam; Peter Tsun-Hon Wong; Kandiah Jeyaseelan
Journal:  Transl Stroke Res       Date:  2010-12       Impact factor: 6.829

Review 9.  Potential function of miRNAs in herpetic stromal keratitis.

Authors:  Sachin Mulik; Siddheshvar Bhela; Barry T Rouse
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

10.  Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy.

Authors:  Nicole R Parker; Nelson Correia; Brendan Crossley; Michael E Buckland; Viive M Howell; Helen R Wheeler
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.